Paromomycin sulfate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
{{DrugProjectFormSinglePage
{{Paromomycin sulfate}}
|authorTag=<!--Overview-->{{RB}}
{{CMG}}
|genericName=Paromomycin sulfate
|aOrAn=a
|drugClass=[[Aminoglycoside]]
|indicationType=treatment
|indication=[[intestinal amebiasis]]–acute and chronic and management of [[hepatic coma]]–as adjunctive therapy.
|adverseReactions=[[Nausea]], [[abdominal cramps]], and [[diarrhea]]


==Overview==
Paromomycin is an [[aminoglycoside]] antibiotic, first isolated from ''Streptomyces krestomuceticus'' in the 1950s.<ref name="Davidson2008">{{cite journal| author = Davidson R.N., den Boer M., Ritmeijer K. | year = 2008 | title = Paromomycin | journal = Transactions of the Royal Society of Tropical Medicine and Hygiene | volume = 103| issue = 7| pages = 653–60| doi = 10.1016/j.trstmh.2008.09.008| pmid = 18947845}}</ref> It was discovered by [[Parke Davis]] now [[Pfizer]] and introduced as ''Humatin'' in 1960.<ref>Page 1166. http://books.google.co.in/books?id=XCsJgUnclbcC&pg=PA1257&dq=Pharmaceutical+Manufacturing+Encyclopedia,+Volume+2&hl=en&sa=X&ei=9V7iT8mqJoOIrAfe4P2zAw&ved=0CDoQ6AEwAA#v=onepage&q=Pharmaceutical%20Manufacturing%20Encyclopedia%2C%20Volume%202&f=false</ref> It is also called monomycin and aminosidine.<ref name="Neal1994">{{cite journal |author= Neal R.A. ''et al''. |year=1994 |title=Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis |journal=Transactions of the Royal Society of Tropical Medicine and Hygiene |volume=88 |issue=2 |pages=223–5 | doi=10.1016/0035-9203(94)90307-7 |pmid= 8036682 }}</ref>


==Category==
Amebicide


==US Brand Names==
<!--Black Box Warning-->
PAROMOMYCIN SULFATE capsule<sup>®</sup>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


==FDA Package Insert==
* Content
'''[[Paromomycin sulfate description|Description]]'''
'''| [[Paromomycin sulfate clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Paromomycin sulfate indications and usage|Indications and Usage]]'''
'''| [[Paromomycin sulfate contraindications|Contraindications]]'''
'''| [[Paromomycin sulfate warnings and precautions|Warnings and Precautions]]'''
'''| [[Paromomycin sulfate adverse reactions|Adverse Reactions]]'''
'''| [[Paromomycin sulfate dosage and administration|Dosage and Administration]]'''
'''| [[Paromomycin sulfate how supplied|How Supplied]]'''
'''| [[Paromomycin sulfate labels and packages|Labels and Packages]]'''


==Mechanisms of Action==
<!--Adult Indications and Dosage-->
Paromomycin is a [[protein synthesis inhibitor]] in non-resistant cells by binding to [[16S ribosomal RNA|16S]] [[ribosomal RNA]].<ref>{{cite journal
| last = Vicens | first = Quentin | coauthors = Eric Westhof
| year = 2001 | month = August
| title = Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site | journal = Structure
| volume = 9 | issue = 8 | pages = 647–658
| doi = 10.1016/S0969-2126(01)00629-3 | pmid = 11587639
| url = http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5
| accessdate = 2007-02-10
}}</ref> This broad spectrum antibiotic soluble in water, is very similar in action to [[Neomycin]]. Antimicrobial activity of Paromomycin against [[Escherichia coli]] and [[Staphylococcus aureus]] has been shown.<ref>{{ cite web | title = Paromomycin | url = http://www.toku-e.com/Upload/Products/PDS/20120518007094.pdf | format = pdf | publisher = Toku-E | date = 2010-01-12 | accessdate = 2012-06-11 }}</ref>


==References==
<!--FDA-Labeled Indications and Dosage (Adult)-->
{{Reflist|2}}
|fdaLIADAdult=====Indications====
* Paromomycin sulfate is indicated for [[intestinal amebiasis]]–acute and chronic (NOTE-It is not effective in [[extraintestinal amebiasis]]); management of [[hepatic coma]]–as adjunctive therapy.


[[Category:Antibiotics]]
* To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
[[Category:Wikinfect]]
 
====Dosage====
* Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.
 
* Management of [[hepatic coma]]:
 
* Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=* Cryptosporidiosis<ref name="pmid8629685">{{cite journal| author=Flanigan TP, Ramratnam B, Graeber C, Hellinger J, Smith D, Wheeler D et al.| title=Prospective trial of paromomycin for cryptosporidiosis in AIDS. | journal=Am J Med | year= 1996 | volume= 100 | issue= 3 | pages= 370-2 | pmid=8629685 | doi=10.1016/S0002-9343(97)89499-5 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8629685  }} </ref>
* Giardiasis<ref name="pmid14049466">{{cite journal| author=DOBON JF, CEDRATO AE, MARTINODECOLOM N| title=[THE USE OF PAROMOMYCIN IN INTESTINAL AMEBIASIS AND GIARDIASIS]. | journal=Dia Med | year= 1963 | volume= 35 | issue=  | pages= 1012 | pmid=14049466 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14049466  }} </ref>
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=====Indications and Dosage====
* Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non-Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|contraindications=* Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.
 
<!--Warnings-->
|warnings=====Precautions====
 
* Prescribing Paromomycin Sulfate Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
 
* The use of this [[antibiotic]], as with other [[antibiotics]], may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patientis essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=* [[Nausea]], [[abdominal cramps]], and [[diarrhea]] have been reported inpatients on doses over 3 g daily.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
 
<!--Drug Interactions-->
|drugInteractions=<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose=There is limited information regarding <i>Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox={{Drugbox2
| Verifiedfields = changed
| verifiedrevid = 476995585
| IUPAC_name = (2''R'',3''S'',4''R'',5''R'',6''S'')-5-amino-6-[(1''R'',2''S'',3''S'',4''R'',6''S'')-<br>4,6-diamino-2-[(2''S'',3''R'',4''R'',5''R'')-4-[(2''R'',3''R'',4''R'',5''R'',6''S'')-<br>3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]<br>oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-<br>3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
| image = Paromomycin wiki str.png
| width = 300
| image2 = Paromomycin ball and stick.png
| drug_name = Paromomycin
 
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|monograph|paromomycin-sulfate}}
| MedlinePlus = a601098
| pregnancy_US = N
| legal_status = Rx only <small>[[U.S.]]</small>
| routes_of_administration = Oral, [[Intramuscular injection|intramuscular]]
 
<!--Pharmacokinetic data-->
| bioavailability = None
| metabolism = None
| elimination_half-life = ?
| excretion = Fecal
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1263-89-4
| ATC_prefix = A07
| ATC_suffix = AA06
| PubChem = 441375
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01421
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 7934
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 390117
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 370143
 
<!--Chemical data-->
| C=23 | H=47 | N=5 | O=18 | S=1
| molecular_weight = 615.629 g/mol
| smiles = O=S(=O)(O)O.O([C@H]3[C@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@H]1O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]1N)[C@H]2O)[C@@H](O)[C@H](N)C[C@@H]3N)[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4N)CO
| InChI = 1/C23H45N5O14.H2O4S/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;1-5(2,3)4/h5-23,29-36H,1-4,24-28H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1
| InChIKey = LJRDOKAZOAKLDU-UDXJMMFXBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H45N5O14.H2O4S/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;1-5(2,3)4/h5-23,29-36H,1-4,24-28H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LJRDOKAZOAKLDU-UDXJMMFXSA-N
}}
 
 
 
 
<!--Mechanism of Action-->
|mechAction=* The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin.
 
<!--Structure-->
|structure=* Paromomycin sulfate is a broad spectrum antibiotic produced by [[Streptomyces riomosus]] var. paromomycinus. It is a white,  amorphous, stable, water-soluble product. Paromomycin sulfate is designated chemically as 0-2, 6-Diamino-2, 6-dideoxy-β -L-idopyranosyl-(1→3)-0-β -D-ribofuranosyl-(1→5)-0-[2-amino-2-deoxy-α -D-glucopyranosyl-(1→4)]-2-deoxystreptamine sulfate (salt). The molecular formula is C23H45N5O14•xH2SO4, with a molecular weight of 615.64 (base).
 
* Its structural formula is:
 
: [[File:Paromomycin str.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=* The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=* Paromomycin Sulfate Capsules, USP each contain paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows:
 
: NDC 23155-038-01: Bottles of 100
 
* The capsule is Dark Blue Opaque /White Opaque, imprinted with “HP 38” in black ink on the cap and on the body.
|storage=* Store at 20°-25°C (68°-77°F)
 
* Protect from moisture.
 
* Preserve in tight containers as defined in the USP.
 
* Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088
|packLabel=====PACKAGE LABEL.PRINCIPAL DISPLAY PANEL====
Paromomycin Sulfate Capsules, USP, 250 mg -100 count
 
: [[File:Paramomycin PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
====Ingredients and Appearance====
 
: [[File:Paramomycin Ing and App.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Patient Counseling Information-->
|fdaPatientInfo=* Patients should be counseled that antibacterial drugs including Paromomycin Sulfate Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Paromomycin Sulfate Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1)  decrease the effectiveness of the immediate treatment and (2)  increase the likelihood that bacteria will develop resistance and will not be treatable by Paromomycin Sulfate Capsules or other antibacterial drugs in the future.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|brandNames=* Humatin®<ref>{{Cite web | title = Paromomycin sulfate | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0f4113-e627-4caf-b2d4-95b4106e57f5}}</ref>
 
<!--Look-Alike Drug Names-->
|lookAlike=<!--Drug Shortage Status-->
|drugShortage=
}}
 
 
 
<!--Pill Image-->
 
 
 
<!--Label Display Image-->
 
 
 
 
 
<!--Category-->
 
[[Category:Drug]]

Latest revision as of 18:20, 26 February 2015

Paromomycin sulfate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Paromomycin sulfate is a Aminoglycoside that is FDA approved for the treatment of intestinal amebiasis–acute and chronic and management of hepatic coma–as adjunctive therapy.. Common adverse reactions include Nausea, abdominal cramps, and diarrhea.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Dosage

  • Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.
  • Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Paromomycin sulfate in adult patients.

Non–Guideline-Supported Use

  • Cryptosporidiosis[1]
  • Giardiasis[2]

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications and Dosage

  • Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Paromomycin sulfate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non-Guideline-Supported Use of Paromomycin sulfate in pediatric patients.

Contraindications

  • Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.

Warnings

Precautions

  • Prescribing Paromomycin Sulfate Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
  • The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patientis essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Paromomycin sulfate in the drug label.

Drug Interactions

There is limited information regarding Paromomycin sulfate Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Paromomycin sulfate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Paromomycin sulfate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Paromomycin sulfate with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Paromomycin sulfate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Paromomycin sulfate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Paromomycin sulfate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Paromomycin sulfate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Paromomycin sulfate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Paromomycin sulfate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Paromomycin sulfate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Paromomycin sulfate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Paromomycin sulfate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Paromomycin sulfate in the drug label.

Overdosage

There is limited information regarding Overdose of Paromomycin sulfate in the drug label.

Pharmacology

Template:Px
Template:Px
Paromomycin
Systematic (IUPAC) name
(2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)-
4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)-
3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]
oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-
3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
Identifiers
CAS number 1263-89-4
ATC code A07AA06
PubChem 441375
DrugBank DB01421
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 615.629 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability None
Metabolism None
Half life ?
Excretion Fecal
Therapeutic considerations
Pregnancy cat.

?(US)

Legal status

Rx only U.S.

Routes Oral, intramuscular

Mechanism of Action

  • The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin.

Structure

  • Paromomycin sulfate is a broad spectrum antibiotic produced by Streptomyces riomosus var. paromomycinus. It is a white, amorphous, stable, water-soluble product. Paromomycin sulfate is designated chemically as 0-2, 6-Diamino-2, 6-dideoxy-β -L-idopyranosyl-(1→3)-0-β -D-ribofuranosyl-(1→5)-0-[2-amino-2-deoxy-α -D-glucopyranosyl-(1→4)]-2-deoxystreptamine sulfate (salt). The molecular formula is C23H45N5O14•xH2SO4, with a molecular weight of 615.64 (base).
  • Its structural formula is:
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Paromomycin sulfate in the drug label.

Pharmacokinetics

  • The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Paromomycin sulfate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Paromomycin sulfate in the drug label.

How Supplied

  • Paromomycin Sulfate Capsules, USP each contain paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows:
NDC 23155-038-01: Bottles of 100
  • The capsule is Dark Blue Opaque /White Opaque, imprinted with “HP 38” in black ink on the cap and on the body.

Storage

  • Store at 20°-25°C (68°-77°F)
  • Protect from moisture.
  • Preserve in tight containers as defined in the USP.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088

Images

Drug Images

{{#ask: Page Name::Paromomycin sulfate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Paromomycin Sulfate Capsules, USP, 250 mg -100 count

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Paromomycin sulfate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

  • Patients should be counseled that antibacterial drugs including Paromomycin Sulfate Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Paromomycin Sulfate Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Paromomycin Sulfate Capsules or other antibacterial drugs in the future.

Precautions with Alcohol

  • Alcohol-Paromomycin sulfate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding Paromomycin sulfate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Flanigan TP, Ramratnam B, Graeber C, Hellinger J, Smith D, Wheeler D; et al. (1996). "Prospective trial of paromomycin for cryptosporidiosis in AIDS". Am J Med. 100 (3): 370–2. doi:10.1016/S0002-9343(97)89499-5. PMID 8629685.
  2. ↑ DOBON JF, CEDRATO AE, MARTINODECOLOM N (1963). "[THE USE OF PAROMOMYCIN IN INTESTINAL AMEBIASIS AND GIARDIASIS]". Dia Med. 35: 1012. PMID 14049466.
  3. ↑ "Paromomycin sulfate".
Retrieved from "https://www.wikidoc.org/index.php?title=Paromomycin_sulfate&oldid=1073785"